Hallucinogen Use Disorders.
Hardaway R, Schweitzer J, Suzuki J.
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):489-96. doi: 10.1016/j.chc.2016.03.006. Epub 2016 Apr 18.
A non-hallucinogenic psychedelic analogue with therapeutic potential.
Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE.
Nature. 2021 Jan;589(7842):474-479. doi: 10.1038/s41586-020-3008-z. Epub 2020 Dec 9.
[Hallucinogenic mushrooms].
Reingardiene D, Vilcinskaite J, Lazauskas R.
Medicina (Kaunas). 2005;41(12):1067-70.
The pharmacology of psilocybin.
Passie T, Seifert J, Schneider U, Emrich HM.
Addict Biol. 2002 Oct;7(4):357-64. doi: 10.1080/1355621021000005937.
Human hallucinogen research: guidelines for safety.
Johnson M, Richards W, Griffiths R.
J Psychopharmacol. 2008 Aug;22(6):603-20. doi: 10.1177/0269881108093587. Epub 2008 Jul 1.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
Griffiths RR, Richards WA, McCann U, Jesse R.
Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92. doi: 10.1007/s00213-006-0457-5. Epub 2006 Jul 7.
A systematic literature review of clinical trials and therapeutic applications of ibogaine.
Köck P, Froelich K, Walter M, Lang U, Dürsteler KM.
J Subst Abuse Treat. 2022 Jul;138:108717. doi: 10.1016/j.jsat.2021.108717. Epub 2021 Dec 30.
Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
Hamill J, Hallak J, Dursun SM, Baker G.
Curr Neuropharmacol. 2019;17(2):108-128. doi: 10.2174/1570159X16666180125095902.
Hallucinogens: an update.
Halpern JH.
Curr Psychiatry Rep. 2003 Oct;5(5):347-54. doi: 10.1007/s11920-003-0067-4.
[Ecstasy toxicity].
Reingardiene D.
Medicina (Kaunas). 2006;42(6):519-23.
